Navigation Links
Alberta Pharmacists Entitled to Prescribe Medicines

Calgary – A new ruling in Alberta empowers pharmacists to prescribe medicines to patients suffering minor medical conditions. Now, pharmacists in Alberta// will be allowed to take a decision on the treatment for minor conditions and make modifications to dosages or prescriptions given by doctors.

Though this ruling has received widespread acclaim, there are certain concerns about the ability of the pharmacists to diagnose medical conditions correctly. Further, it is not clear as to who will take the ultimate responsibility when difference of opinion between doctors and pharmacists arise.

Pharmacists have praised this move, as it will ease the pressure on family physicians and reduce waiting times in emergency rooms. Jeff Poston, executive director of the Canadian Pharmacists Association, said, "There are numerous examples where I think patients can get treatment for a number of disorders from a community pharmacy. They don't need to see the physician, they don't need to go to the ER and the pharmacist is going to be perfectly competent in terms of managing them. Pharmacists are not going to be stupid about this. The patient who's got a headache and is also dizzy and has blurred vision, you're not going to sell them a new headache tablet. You're going to refer them to the emergency room straight away."

Some medical specialists have pointed out that such a ruling may be risky, as critical conditions could go unnoticed till it is too late. After all, pharmacists cannot step into Doctors’ shoes so effortlessly, by virtue of the knowledge and experience doctors possess in their respective fields of medicine. Only time will tell if the decision to empower pharmacists is a shot in the arm or the biggest blunder.
SAV/
'"/>




Page: 1

Related medicine news :

1. Alberta’s New Reform Plans In Health Care Secto
2. 100 cases of CWD reported in Alberta
3. Alberta pharmacists vested with authority to prescribe
4. Approval imminent for Herceptin in Alberta
5. Alberta Most Affected By Influenza
6. Chronic Wasting Disease In Alberta
7. Albertas Mental Health Act Welcomed
8. New Medicare Plan - Mixed Reaction among Pharmacists.
9. Manitoba Ombudsman Warns Pharmacists
10. Hospitalized patients better of with help from Pharmacists
11. Pharmacy Board Says Pharmacists Have Right To Refuse Morning-After Pill
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... cream that’s the first in a new class of photodynamic cosmetics (PDC). , ... of skin, visibly reduce outward signs of aging, and minimize the appearance of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... targets, they rely on contracted partners to help with process innovation in drug ... combined drug formulation experience along with state-of-the-art analytical equipment in support of their ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: